You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

SAVELLA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Savella patents expire, and what generic alternatives are available?

Savella is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-three patent family members in twenty-three countries.

The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Savella

Savella was eligible for patent challenges on January 14, 2013.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are five tentative approvals for the generic drug (milnacipran hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Drug patent expirations by year for SAVELLA
Drug Prices for SAVELLA

See drug prices for SAVELLA

Drug Sales Revenue Trends for SAVELLA

See drug sales revenues for SAVELLA

Recent Clinical Trials for SAVELLA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 4
University of OttawaPhase 4
Research Foundation for Mental Hygiene, Inc.N/A

See all SAVELLA clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SAVELLA
Paragraph IV (Patent) Challenges for SAVELLA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SAVELLA Tablets milnacipran hydrochloride 12.5 mg, 25 mg, 50 mg, and 100 mg 022256 8 2013-01-14

US Patents and Regulatory Information for SAVELLA

SAVELLA is protected by one US patents.

Patents protecting SAVELLA

Milnacipran for the long-term treatment of fibromyalgia syndrome
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: MANAGEMENT OF FIBROMYALGIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SAVELLA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 ⤷  Sign Up ⤷  Sign Up
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 ⤷  Sign Up ⤷  Sign Up
Abbvie SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for SAVELLA

See the table below for patents covering SAVELLA around the world.

Country Patent Number Title Estimated Expiration
Japan 2009510080 ⤷  Sign Up
Singapore 183735 MILNACIPRAN FOR THE LONG-TERM TREATMENT OF FIBROMYALGIA SYNDROME ⤷  Sign Up
Canada 2624018 MILNACIPRAN POUR LE TRAITEMENT A LONG TERME DU SYNDROME DE LA FIBROMYALGIE (MILNACIPRAN FOR THE LONG-TERM TREATMENT OF FIBROMYALGIA SYNDROME) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.